E
Bionano Genomics, Inc.
BNGO
$4.08
-$0.02-0.49%
E
Sell
10/19/2023Downgrade
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 10/19/2023 due to a decline in the total return index and volatility index.
D
Sell
8/14/2023Upgraded
Bionano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 8/14/2023 due to an increase in the valuation index.
Bionano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 8/14/2023 due to an increase in the valuation index.
E
Sell
8/7/2023Downgrade
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 8/7/2023 due to a decline in the solvency index, valuation index and total return index. The quick ratio declined from 3.36 to 2.69.
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 8/7/2023 due to a decline in the solvency index, valuation index and total return index. The quick ratio declined from 3.36 to 2.69.
D
Sell
3/14/2023Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the solvency index, growth index and total return index. The quick ratio declined from 5.55 to 3.36, earnings per share declined from -$0.11 to -$0.1302, and operating cash flow declined 17.11% from -$29.47M to -$34.52M.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 3/14/2023 due to a noticeable decline in the solvency index, growth index and total return index. The quick ratio declined from 5.55 to 3.36, earnings per share declined from -$0.11 to -$0.1302, and operating cash flow declined 17.11% from -$29.47M to -$34.52M.
D
Sell
2/23/2023Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 2/23/2023 due to an increase in the volatility index and valuation index.
D
Sell
2/8/2023Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 6.89 to 5.55.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 2/8/2023 due to a decline in the total return index and solvency index. The quick ratio declined from 6.89 to 5.55.
D
Sell
5/31/2022Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/31/2022 due to an increase in the volatility index and total return index.
D
Sell
5/13/2022Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and growth index. Earnings per share declined from -$0.0808 to -$0.1052, operating cash flow declined 26.82% from -$25.62M to -$32.49M, and EBIT declined 9.75% from -$27.28M to -$29.94M.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 5/13/2022 due to a decline in the solvency index and growth index. Earnings per share declined from -$0.0808 to -$0.1052, operating cash flow declined 26.82% from -$25.62M to -$32.49M, and EBIT declined 9.75% from -$27.28M to -$29.94M.
D
Sell
5/5/2022Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/5/2022 due to an increase in the valuation index.
D
Sell
4/20/2022Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 4/20/2022 due to a decline in the total return index and volatility index.
D
Sell
11/9/2021Upgraded
Bionano Genomics, Inc. (BNGO) was upgraded to D from E+ on 11/09/2021.
Bionano Genomics, Inc. (BNGO) was upgraded to D from E+ on 11/09/2021.
E
Sell
11/8/2021Downgrade
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D on 11/08/2021.
Bionano Genomics, Inc. (BNGO) was downgraded to E+ from D on 11/08/2021.
D
Sell
12/30/2020Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 12/30/2020 due to an increase in the volatility index, total return index and growth index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 12/30/2020 due to an increase in the volatility index, total return index and growth index.
D
Sell
11/16/2020Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 11/16/2020 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 51.84% from -$7.22M to -$10.96M, EBIT declined 37.55% from -$7.44M to -$10.23M, and the quick ratio declined from 1.05 to 0.92.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 11/16/2020 due to a decline in the growth index, solvency index and volatility index. Operating cash flow declined 51.84% from -$7.22M to -$10.96M, EBIT declined 37.55% from -$7.44M to -$10.23M, and the quick ratio declined from 1.05 to 0.92.
D
Sell
8/14/2020Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 8/14/2020 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2955 to -$0.09, EBIT increased 23.84% from -$9.76M to -$7.44M, and operating cash flow increased 10.13% from -$8.03M to -$7.22M.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 8/14/2020 due to an increase in the growth index, volatility index and total return index. Earnings per share increased from -$0.2955 to -$0.09, EBIT increased 23.84% from -$9.76M to -$7.44M, and operating cash flow increased 10.13% from -$8.03M to -$7.22M.
D
Sell
6/2/2020Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 6/2/2020 due to a decline in the valuation index, volatility index and total return index.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 6/2/2020 due to a decline in the valuation index, volatility index and total return index.
D
Sell
5/1/2020Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the solvency index, valuation index and growth index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 5/1/2020 due to a noticeable increase in the solvency index, valuation index and growth index.
D
Sell
3/27/2020Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 3/27/2020 due to an increase in the valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 3/27/2020 due to an increase in the valuation index.
E
Sell
3/12/2020Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 3/12/2020 due to a noticeable decline in the solvency index, valuation index and efficiency index. Debt to equity increased from -2.67 to 5.56, the quick ratio declined from 1.91 to 0.9, and net income declined 23.48% from -$6.4M to -$7.9M.
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 3/12/2020 due to a noticeable decline in the solvency index, valuation index and efficiency index. Debt to equity increased from -2.67 to 5.56, the quick ratio declined from 1.91 to 0.9, and net income declined 23.48% from -$6.4M to -$7.9M.
D
Sell
3/3/2020Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 3/3/2020 due to a decline in the volatility index.
BioNano Genomics, Inc. (BNGO) was downgraded to D- from D on 3/3/2020 due to a decline in the volatility index.
D
Sell
2/12/2020Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 2/12/2020 due to an increase in the volatility index and total return index.
BioNano Genomics, Inc. (BNGO) was upgraded to D from D- on 2/12/2020 due to an increase in the volatility index and total return index.
D
Sell
11/12/2019Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 11/12/2019 due to an increase in the efficiency index, growth index and valuation index. Total revenue increased 52.35% from $2.17M to $3.31M, EBIT increased 16.94% from -$6.84M to -$5.69M, and net income increased 16.52% from -$7.66M to -$6.4M.
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 11/12/2019 due to an increase in the efficiency index, growth index and valuation index. Total revenue increased 52.35% from $2.17M to $3.31M, EBIT increased 16.94% from -$6.84M to -$5.69M, and net income increased 16.52% from -$7.66M to -$6.4M.
E
Sell
8/23/2019Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 8/23/2019 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 25.44% from $24.25M to $18.08M.
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 8/23/2019 due to a decline in the volatility index, total return index and efficiency index. Total capital declined 25.44% from $24.25M to $18.08M.
D
Sell
8/8/2019Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 8/8/2019 due to an increase in the valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 8/8/2019 due to an increase in the valuation index.
E
Sell
7/19/2019Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 7/19/2019 due to a decline in the total return index and volatility index.
BioNano Genomics, Inc. (BNGO) was downgraded to E+ from D- on 7/19/2019 due to a decline in the total return index and volatility index.
D
Sell
7/1/2019Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 7/1/2019 due to an increase in the valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to D- from E+ on 7/1/2019 due to an increase in the valuation index.
E
Sell
6/3/2019Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to E+ from E on 6/3/2019 due to an increase in the efficiency index. Total capital increased 26.5% from $19.17M to $24.25M.
BioNano Genomics, Inc. (BNGO) was upgraded to E+ from E on 6/3/2019 due to an increase in the efficiency index. Total capital increased 26.5% from $19.17M to $24.25M.
E
Sell
3/4/2019Upgraded
BioNano Genomics, Inc. (BNGO) was upgraded to E from E- on 3/4/2019 due to an increase in the valuation index.
BioNano Genomics, Inc. (BNGO) was upgraded to E from E- on 3/4/2019 due to an increase in the valuation index.
E
Sell
12/21/2018Downgrade
BioNano Genomics, Inc. (BNGO) was downgraded to E- from E on 12/21/2018 due to a large decline in the volatility index.
BioNano Genomics, Inc. (BNGO) was downgraded to E- from E on 12/21/2018 due to a large decline in the volatility index.
E
Sell
12/17/2018None
Bionano Genomics, Inc. (BNGO) was downgraded to E from U on 12/17/2018.
Bionano Genomics, Inc. (BNGO) was downgraded to E from U on 12/17/2018.
NASDAQ
03/07/2025 4:00PM Eastern
Quotes delayed
